永泰生物-B(06978.HK)就北京建研發及產業化基地訂建造協議 涉逾6.6億人幣
永泰生物-B(06978.HK)公布,公司透過其間接全資附屬北京永泰與承建商中建三局訂立建造協議,內容有關於中國北京興建研發及產業化基地,合約金額為6.65億元人民幣。
中建三局將負責進行研發及產業化基地的建設及工程作業,該基地的總地盤面3.5萬平方米,總施工面積為12.1萬平方米。建造工程包括多幢用作質檢、綜合用途、細胞療法及其他生產車間、倉庫及雨水收集缸的建築物。預計建造期由今年3月15日至2023年9月1日。(ek/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.